Ahmed Tawakol, MD
Cardiovascular Disease · Boston, MANPI 1649257080
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,435 of the $15,785 with a category attached, or 97.8%. Genentech, Inc. accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $9,555, more than ten times the $84 reported in 2023.
Across 5 payments — averaging $3157.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$16K
- Novartis$84
Across 9 payments — averaging $64,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$583K
What the payments were for
- Consulting fees$15,43598%
- Travel & lodging$1171%
- Food & beverage$2341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 4 | $15,701 |
| Novartis | 1 | $84 |
How this compares
$15,785 in reported general payments places this provider in the 80th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 36 | $787 |
| Rosuvastatin Calcium | 16 | $465 |
| Atorvastatin Calcium | 31 | $310 |
| Amlodipine Besylate | 21 | $241 |
| Losartan Potassium | 14 | $98 |
| Lisinopril | 23 | $97 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.